Mr. Irwin Simon reports

TILRAY BRANDS POSITIONED FOR U.S. EXPANSION AMID HISTORIC CANNABIS RESCHEDULING

Tilray Brands Inc. has issued a statement applauding President Donald Trump's actions leading to rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act -- a defining inflection point that represents a fundamental shift in U.S. drug policy, unlocking significant opportunities for medical cannabis clinical research, patient access and industry standardization. The action represents the most consequential federal cannabis policy development in decades, accelerating the emergence of a regulated, science-driven medical cannabis framework in the United States.

Irwin D. Simon, chairman and chief executive officer, Tilray Brands, stated: "Today marks a pivotal moment for the United States. With President Trump's action to reschedule cannabis, federal policy is finally aligning with science, medicine and, most importantly, patient needs. This is about people: patients fighting cancer, seniors managing chronic pain, veterans navigating PTSD and children with epilepsy whose families have long sought safe, effective options. For decades, they have turned to medical cannabis. Today, the system begins to catch up with them. Rescheduling has the potential to accelerate clinical research, broaden access, and elevate the quality, consistency and safety standards that establish medical cannabis as a legitimate pillar of modern health care.

"At Tilray, we have built a global platform for precisely this moment. We are among the world's largest cannabis growers with more than seven million square feet of cultivation capacity and a recognized global leader across pharmaceutical-grade, cannabis production, clinical research, product innovation and patient care. Through Tilray Medical, we have served hundreds of thousands of patients across more than 20 countries in some of the world's most stringently regulated markets. This is how health care evolves. Tilray stands ready to partner with regulators and health care providers to responsibly expand access to medical cannabis and help shape the future of this industry in the United States."

Tilray Medical

Tilray Medical brings a competitive foundation few can match: a proven record operating at scale across more than 20 highly regulated international markets, pharmaceutical-quality cultivation, manufacturing and distribution infrastructure, and deep regulatory fluency developed through years of engagement with health care authorities around the world and navigating complex regulatory frameworks. Having supported hundreds of thousands of patients globally through a broad portfolio of cannabinoid formulations including cannabidiol- and tetrahydrocannabinol-based products across beverages, edibles, topicals and additional formats, Tilray Medical is prepared to bring that same standard of care, quality and compliance to U.S. patients.

As U.S. federal policy reaches an inflection point, Tilray is uniquely positioned to lead the emergence of a regulated medical cannabis market. Tilray is actively evaluating participation in the Center for Medicare and Medicaid Innovation pilot program, which would position the company as a supply partner to accountable care organizations and oncology practices delivering hemp-derived medical cannabis to underserved and vulnerable patient populations while generating clinical outcomes data that will help shape the standards of an emerging regulated industry.

About Tilray Brands Inc.

Tilray Brands is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness and entertainment elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.

We seek Safe Harbor.